The future of MS biomarkers: key takeaways from ACTRIMS 2022

ACTRIMS 2022 highlighted novel scientific discoveries for multiple sclerosis (MS), with a focus on MS biomarkers. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, from better, novel treatments to the potential of enhanced AI-based neuroimaging for improved patient management.

Continue ReadingThe future of MS biomarkers: key takeaways from ACTRIMS 2022